Weighted (40 / 30 / 20 / 10) into the 7.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 67%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Values & turf — what this means
A trade-off or turf question that more data alone won't settle — it turns on risk tolerance, cost, or which specialty owns the decision.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (3 vs 1 here). The bar shows how that lean divides between the two camps.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (20 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
01★ Top debateSpecialist debate
Cath the frail 80-year-old, or not?
Cath the frail 80-year-old with NSTEMI, or treat with medicines?
Thousands of very old patients a year either get wheeled to the cath lab out of habit, or get told medicines are enough — and for the frailest, the wrong default may shorten life rather than extend it.
Outlook: A judgment call — more data alone won't fully settle it
In patients 75 and older with NSTEMI who are severely frail, should severe frailty itself shift the default from routine angiography to medical therapy — given a neutral primary outcome and only a subgroup signal of harm?
Cath by default
Angiography in older patients turned out to be safe with almost no procedural complications, it cut repeat heart attacks, and judging who is 'too frail' by eyeball is exactly how older patients have been undertreated for decades.
“The SENIOR-RITA trial is the largest trial to date in older adults with heart attacks than all previous trials combined. Among older adults with type 1 NSTEMI, an invasive strategy is safe.”
“An invasive strategy did not reduce the primary endpoint, but we did see some benefits. Importantly, the invasive strategy appeared to be safe overall in our older patients.”
Vijay Kunadian ·
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
How much practice changes7.5 · 30%
How much is genuinely new9.1 · 20%
Clinician attention8.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (8 vs 2 here). The bar shows how that lean divides between the two camps — the grey middle is the 17 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (46 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Oct 2024).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
02Field-wide debate
Bust the clot or just anticoagulate in submassive PE?
Thrombolysis or anticoagulation alone for intermediate-risk PE?
Resolve this and you decide whether thousands of stable PE patients with a strained right ventricle get an invasive clot-busting procedure with bleeding risk, or just blood thinners and watchful waiting.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes8.0 · 30%
How much is genuinely new7.4 · 20%
Clinician attention7.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.7 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 75%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Values & turf — what this means
A trade-off or turf question that more data alone won't settle — it turns on risk tolerance, cost, or which specialty owns the decision.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (10 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 20 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (56 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2024).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
03Field-wide debate
Add finerenone on top of SGLT2 inhibitors in HFpEF?
Finerenone in HFpEF with CKD and diabetes: add to SGLT2i?
Layer two pricey drugs on every diabetic HFpEF patient with kidney disease and you may cut more events — or just add cost and potassium scares for little extra gain.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.0 · 40%
How much practice changes8.5 · 30%
How much is genuinely new9.1 · 20%
Clinician attention7.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.9 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 86%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Coordination gap — what this means
The answer is roughly known, but everyday practice and guidelines lag behind the evidence. The fight is about adoption, not the science.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (11 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 78 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (155 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Apr 2024).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
04Field-wide debate
Role of CAC scoring in intermediate-risk patients per 2026 ACC/AHA dyslipidemia guideline
Get the thresholds wrong and millions of low-risk adults start lifelong statins they may never have needed — or get them right and you finally catch the patients who slip through current risk scores.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.3 · 40%
How much practice changes9.0 · 30%
How much is genuinely new8.5 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.2 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (6 vs 2 here). The bar shows how that lean divides between the two camps — the grey middle is the 58 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (66 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jun 2020).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
05Field-wide debate
Watchman FLX as first-line vs NOACs in eligible AF patients?
Get this wrong and a generation of stroke-eligible AF patients trades a daily pill they could safely take for a permanent implant that may leave them more prone to stroke.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
How much practice changes7.5 · 30%
How much is genuinely new8.5 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.0 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 67%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (6 vs 3 here). The bar shows how that lean divides between the two camps — the grey middle is the 11 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (37 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jan 2025).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
06Field-wide debate
Do the new ACS guidelines contradict themselves?
Gray areas in 2025 ACC/AHA ACS guidelines: what to do with conflicting recommendations?
How cardiologists read the fine print of one guideline decides whether millions of heart attack patients get a year of dual antiplatelet therapy or an early de-escalation — and which P2Y12 drug they walk out on.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes8.5 · 30%
How much is genuinely new8.5 · 20%
Clinician attention8.0 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.1 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (5 vs 3 here). The bar shows how that lean divides between the two camps — the grey middle is the 18 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (47 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Sep 2019).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
07Field-wide debate
Drop aspirin early after a heart attack?
Shorter DAPT or earlier aspirin withdrawal after ACS?
Cut aspirin too soon and high-risk patients throw clots; keep it too long and they bleed — this decides the default regimen for nearly everyone leaving the cath lab after ACS.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
How much practice changes8.5 · 30%
How much is genuinely new9.4 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 8.3 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 81%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (9 vs 3 here). The bar shows how that lean divides between the two camps — the grey middle is the 39 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (61 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Jan 2024).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
08Field-wide debate
Replace the valve before symptoms hit?
TAVR for asymptomatic severe aortic stenosis or watchful waiting?
Get this wrong and patients with no symptoms get a valve they didn't need yet — or wait until the heart is already damaged.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.8 · 40%
How much practice changes8.5 · 30%
How much is genuinely new8.3 · 20%
Clinician attention7.7 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.3 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 89%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Values & turf — what this means
A trade-off or turf question that more data alone won't settle — it turns on risk tolerance, cost, or which specialty owns the decision.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (8 vs 3 here). The bar shows how that lean divides between the two camps — the grey middle is the 8 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (29 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Oct 2025).
On the boardhow long the question has been live on Synapse (3 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
09Field-wide debate
PCSK9 shots for high-risk patients who've never had an event?
Evolocumab or standard care in primary prevention without prior events?
If this expands, millions of statin-treated patients with diabetes or plaque but no prior heart attack become candidates for an expensive lifelong injectable.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.3 · 40%
How much practice changes7.5 · 30%
How much is genuinely new8.2 · 20%
Clinician attention7.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.4 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 86%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (1 vs 4 here). The bar shows how that lean divides between the two camps — the grey middle is the 33 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (90 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Apr 2024).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
10Field-wide debate
Drop aspirin one month after a heart attack?
Default 12-month DAPT in ACS or shorter duration in lower-risk patients?
Nearly every patient stented for a heart attack now faces a choice at one month: stay on two blood thinners for a year and accept the bleeds, or drop aspirin early and trust that clots won't come back.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is9.0 · 40%
How much practice changes7.0 · 30%
How much is genuinely new8.8 · 20%
Clinician attention7.6 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.1 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Evidence gap — what this means
The answer is genuinely unknown and a trial or readout is still pending. New data we don't have yet will settle it.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (6 vs 4 here). The bar shows how that lean divides between the two camps — the grey middle is the 8 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (42 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Oct 2024).
On the boardhow long the question has been live on Synapse (2 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
11Field-wide debate
Clip a leaky tricuspid to save lives?
Clip a leaky tricuspid valve, or is quality of life just a placebo?
If the new survival signal holds, thousands of elderly patients with a leaky tricuspid valve get a procedure that keeps them out of the hospital — if it doesn't, they get an expensive fix that only makes them feel better for a while.
Heat — how live this debate is
A 0–10 estimate of how live and consequential this disagreement is in cardiology right now. It drives the ranking.
This debate’s factors
How split the field is8.5 · 40%
How much practice changes8.5 · 30%
How much is genuinely new9.1 · 20%
Clinician attention8.3 · 10%
Weighted (40 / 30 / 20 / 10) into the 7.2 heat score.
1.A continuous scan (Grok, with live web access) reads the cardiology literature, FDA actions, new guidelines, and the clinician conversation on X to find genuinely contested questions and gather the evidence behind them.
2.Two AI reviewers from different model families — Claude and GPT-5 — then independently rate four factors, led by how genuinely the field disagrees, plus how much practice changes, how much genuinely new evidence there is, and how much real clinician (not lay) attention it draws. Neither sees the other’s ratings.
3.Key factors are grounded in real signals we collected — named experts quoted on opposing sides, and actual new trials, guidelines, or FDA actions — so heat isn’t just the models’ opinion.
4.Fixed editorial weights combine the factors — models never set the weights.
5.Scores are smoothed across scans, so one viral moment can’t whipsaw the board.
On this topic, the two reviewers’ ratings agreed 92%.
Heat is an AI estimate, not a vote — no cardiologist has voted on it yet. As cardiologists vote on Synapse, measured expert disagreement replaces this AI estimate as the headline number.
Movement — vs the previous scan
The board re-ranks after every scan. This chip is measured bookkeeping, not a model’s opinion:
▲ / ▼ — places climbed or dropped since the last scan.
NEW — first appearance on the board.
— — held its position.
Positions only swap when a debate’s heat moves decisively; small wobbles never reshuffle the board.
Coordination gap — what this means
The answer is roughly known, but everyday practice and guidelines lag behind the evidence. The fight is about adoption, not the science.
The type sets how the debate is framed below — an evidence gap leads with the pending trial, a coordination gap with the two camps, a values & turf split with the trade-off.
Patient reach — how many this affects
A coarse sense of how big the affected patient population is — from a small subspecialty group (“Few patients”) up to millions in routine practice (“Millions of patients”).
It’s a magnitude band the model sets from the clinical context, not a counted total — we never show a fabricated patient number. This is a display signal and doesn’t change the heat score.
Expert split — who’s on record
The tally of named experts we found publicly taking each side (6 vs 1 here). The bar shows how that lean divides between the two camps — the grey middle is the 55 on record whose position doesn’t map cleanly onto either camp. We never force a named clinician into a side.
This is who we found on the record — a snapshot, not a full poll of the field. The measured split will come from cardiologists voting on Synapse.
Sources — the evidence behind it
How many distinct sources we linked for this debate (51 sources here) — journals, guidelines, FDA actions, preprints, news, and posts on X. More bars mean deeper coverage.
Open “The evidence” below to see each one. Counts and quotes are scan-reported and link to their primary source — not yet independently verified.
Two clocks: active since vs. on the board
These measure different things, so the card keeps them apart:
Active sincewhen the real-world debate became active, from the earliest dated source we found (Apr 2024).
On the boardhow long the question has been live on Synapse (4 mo).
A debate can be contested for years but new to the board — or brand-new science that’s only days old.
12Field-wide debate
Continuing beta-blockers long-term after uncomplicated MI
Get this wrong and millions of stable post-MI patients either swallow a daily pill for nothing or lose real arrhythmia and remodeling protection.
Debates are surfaced by a continuous scan of the cardiology literature and the conversation among clinicians. The heat score (0-10) reflects how live and consequential the disagreement is right now and drives the ranking; it becomes the measured expert split as cardiologists weigh in. Quotes and engagement counts are scan-reported and link to their primary source.
The trial showed no survival benefit, and at the highest levels of frailty the signal tipped toward harm — so in a patient with limited reserve and dementia, an invasive workup buys procedures and hospital days instead of better years.
“Patients who are severely frail can be treated with medical therapy alone.”
Named experts we found publicly on record — a sample, not a representative poll of the field.
3Cath by default1Medicines first when frail
Named experts on the record — a snapshot from the scan, not a poll. The measured clinician split builds below.
Where do you land?
No votes yet — the measured split appears at 10.
Some details are pending source verification and are withheld until confirmed.
Who: Adults ≥75 years with type 1 NSTEMI, including frail patients·20 sources
On the board:since Aug 28, 2026 (2 mo)— time live on Synapse
Patients affected:Many patients· heart attacks are common in the very old
›The evidence
What we know
✓In the largest trial in older heart attack patients, routine angiography did not lower the combined risk of cardiovascular death or another heart attack over about four years.
✓Nonfatal heart attacks were less frequent with the invasive approach; deaths were not.
✓The procedure itself was safe — serious complications occurred in under 1% of patients.
✓Current guidelines still lean invasive for this type of heart attack, regardless of age.
What's still unknown
?Whether the hint of harm in the most frail patients is real or a subgroup artifact — it has not been tested prospectively.
?Where on the frailty scale the benefit flips to harm, and whether any single frailty tool should drive the decision.
?How patients with meaningful cognitive impairment fare, since they are thinly represented in trials.
?Whether outcomes patients care about — independence, symptoms, days at home — favor one strategy.
For intermediate-to-high-risk PE with RV strain and positive troponin but stable hemodynamics, should clinicians use early catheter-directed thrombolysis or reserve it and start with anticoagulation alone?
Intervene early
Catheter-directed thrombolysis unloads the strained right ventricle faster and may cut the chance a stable patient suddenly crashes, instead of waiting for deterioration that's hard to reverse.
“ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation led to a lower risk”
“The study largely confirms what a lot of people in the PE world have suspected, which is that the use of catheter-based interventions, including catheter-based thrombolysis, improves patient outcomes.”
“This trial shows that a catheter intervention can indeed be effective and improve the prognosis for patients with severe PE and elevated risk of early death or life-threatening complications.”
Stavros V. Konstantinides · HI-PEITHO lead author · ACC ↗
Anticoagulate first
Most intermediate-risk patients do fine on blood thinners alone, so adding a procedure exposes them to bleeding and cost for a benefit that may only exist in a narrow sicker subset.
“For the majority of patients with intermediate-risk PE, anticoagulation remains the right treatment. For the narrow subset with objective evidence of RV strain, positive troponin, and clinical signs of physiologic stress, CDT now has RCT evidence supporting its use.”
“CDT should be considered for patients with high-risk PE, in whom thrombolysis is contraindicated or has failed. Also, CDT is a treatment option for initially stable patients in whom anticoagulant treatment fails.”
Piotr Pruszczyk · ESC Working Group on Pulmonary Circulation · EuroIntervention ↗
Undecided
“This guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care for people with this condition.”
In HFpEF patients with type 2 diabetes and CKD already on an SGLT2 inhibitor, should finerenone be added routinely given only indirect and real-world evidence of additive benefit?
Stack both drugs
Finerenone and SGLT2 inhibitors hit different pathways, real-world signals show fewer deaths and admissions when combined, and SGLT2 inhibitors may even blunt the potassium rise.
“We’ve seen the primary data. The primary data showed that it was safe to use them both. We got additive amounts of proteinuria reduction, but there [were] some cross-signals in terms of the hyperkalemia.”
“In patients with HFpEF and diabetic CKD stages 3-5, addition of finerenone to SGLT2 inhibitor therapy was associated with significant reductions in all-cause mortality and hospitalizations, without increased hyperkalemia risk despite advanced renal dysfunction.”
“with finerenone, what we see actually is that this is another trial, actually, in heart—in this population of individuals with HFpEF or HFmrEF—a population that’s historically been very difficult to treat and historically lacking in proven therapies. And this is really the second”
John Ostrominski · Fellow of Cardiovascular Medicine and Obesity Medicine · Pharmacy Times ↗
“Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF.”
Scott Solomon · Senior Physician and Director of Noninvasive Cardiology · TCTMD ↗
“Evidence increasingly suggests that combining SGLT2 inhibition and finerenone may provide additive benefits, but it has not been proven.”
“We had seen a meta-analysis beforehand by Brendon Neuen that showed that we would get less hyperkalemia when we combine finerenone plus SGLT2 inhibitors.”
Brendon Neuen · Nephrologist and clinical researcher · DocWire News ↗
“Finerenone improved outcomes in HFmrEF and HFpEF.”
“Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF.”
“In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo.”
The added benefit over an SGLT2 inhibitor alone in HFpEF is unproven, and finerenone still carries hyperkalemia risk and cost that aren't justified without dedicated trial data.
“In the FINEARTS trial, finerenone produced an 18% reduction in the risk of hospitalizations for heart failure but yielded uninterpretable and clinically questionable changes in KCCQ, with the small possibility of a modest benefit in <2% of randomized patients.”
In borderline/intermediate-risk primary prevention adults, should PREVENT-driven lower thresholds and universal Lp(a) testing trigger statin therapy now, or should CAC scoring be required to confirm risk before treating?
Appropriately intensifies prevention
Lower thresholds plus once-in-a-lifetime Lp(a) testing catch high-risk people that older risk equations miss, and starting statins earlier in the right patients prevents events decades down the line.
“The guideline supports Lp(a) measurement at least once in all adults to refine ASCVD risk assessment.”
Robert S. Blumenthal · Guideline writing committee chair · JACC ↗
“There is indeed overwhelming evidence supporting our practice-changing Guideline.”
Roger S. Blumenthal · Guideline writing committee chair · Medscape ↗
“Universal lipid testing and management... promoting the importance of preventing the onset of dyslipidemia.”
Many of these new Class I recommendations rest on modeling and observational data rather than randomized outcome trials, so lowering the bar risks medicating large numbers of people who would never have had an event.
“Too many Class I recommendations lacking supporting data from randomized trials.”
John Mandrola · Cardiologist and Medscape commentator · Medscape ↗
Undecided
“It’s a big change, going from the Pooled Cohort Equations to PREVENT.”
In AF patients fully eligible for long-term anticoagulation, should left atrial appendage closure be offered as a first-line alternative to NOACs given a noninferior composite but a higher ischemic stroke signal?
Offer the device early
Trials met noninferiority for the hard composite while cutting serious nonprocedural bleeding, so patients who hate or fear lifelong anticoagulation finally have a real alternative without waiting to fail pills first.
“LAA occlusion remained noninferior to DOAC therapy in terms of the primary composite endpoint.”
The numerically higher ischemic stroke signal, soft composite endpoints, and industry funding mean we can't yet call a one-time implant equal to a proven drug we can stop if something goes wrong.
“I’m not convinced that these devices should be considered an equal substitute for NOACs.”
“If positive, the results of our trial will create a new paradigm of combining mechanical and medical strategies to prevent stroke among patients with AF who are at higher risk of stroke.”
Jeff Healey · Cardiologist/Electrophysiologist · PHRI ↗
“CHAMPION-AF 3-Year Results and Implications for the Future of Left Atrial Appendage Closure”
Matthew Sherwood · Interventional Cardiologist · JIC ↗Harriette Van Spall · McMaster University cardiologist · Radcliffe ↗
Named experts we found publicly on record — a sample, not a representative poll of the field.
6Offer the device early58unplaced2Keep pills first-line
Named experts on the record — a snapshot from the scan, not a poll. The measured clinician split builds below.
For ACS patients undergoing PCI under the 2025 ACC/AHA guideline, should the competing Class 1 antiplatelet recommendations be treated as needing formal clarification before they guide care, or as intended flexibility to individualize therapy?
Fix the conflicts first
The guideline carries competing Class 1 recommendations — a full year of dual antiplatelet therapy to cut ischemic events alongside shortening or de-escalating it to cut bleeding — and clinicians can't apply both, so the document needs clarification before it drives practice.
“The 2025 ACC/AHA ACS guidelines remain an area that's still controversial.”
“some recommendations may benefit from clarification to improve internal alignment. For example, the guideline includes Class 1 recommendations both for DAPT for 1 year (to reduce ischemic events) and for switching to ticagrelor monotherapy after 1 month of tolerating DAPT (to red”
“A paradigmatic example is the recommendation of the P2Y12 inhibitor of choice in ACS patients proceeding to PCI: the ESC guideline recommend prasugrel over ticagrelor based on the ISAR REACT 5 trial, whereas for the American guideline, both agents are equally recommended.”
“A paradigmatic example is the recommendation of the P2Y12 inhibitor of choice in ACS patients proceeding to PCI: the ESC guideline recommend prasugrel over ticagrelor based on the ISAR REACT 5 trial, whereas for the American guideline, both agents are equally recommended.”
“the 2025 guidelines for the management of acute coronary syndromes (ACS) are exhaustive and relatively all-inclusive, recent research has highlighted the presence of gray areas, controversies”
Merging STEMI and NSTEMI into one framework finally aligns practice with a decade of trials, and the flexibility clinicians read as 'conflict' is really room to individualize between ischemic and bleeding risk.
“By grouping STEMI and NSTEMI together, she added, “I’m really hoping that it’s going to make everybody much more comfortable because we had clinical trials that came out, but the guidelines were so out of date.””
Jacqueline E. Tamis-Holland · Cardiologist · TCTMD ↗
“intracoronary imaging is recommended to guide PCI in patients with ACS with complex coronary lesions”
“Use intracoronary imaging to guide percutaneous coronary intervention (PCI). This recommendation was not included in prior STEMI and NSTEMI guidelines... elevated to a class 1”
In post-ACS patients on dual antiplatelet therapy, should aspirin be withdrawn at 1-3 months in favor of P2Y12 monotherapy, or should the standard 12-month regimen continue until powered trials identify who can safely de-escalate?
De-escalate early
Pulling aspirin at 1-3 months and running P2Y12 monotherapy cuts bleeding without a clear ischemic penalty, so the old 12-month dual regimen overtreats most patients.
“In high-risk PCI patients, further ischemic events remain a life-threatening concern. As seen in TWILIGHT, in patients who tolerated three months of dual antiplatelet therapy, lowering the risk of major bleeding while preserving the ischemic benefit using ticagrelor monotherapy i”
“Abbreviation of DAPT duration after 1–6 months, followed by monotherapy with aspirin or a P2Y12 inhibitor, reduces bleeding without an increase in ischaemic events in patients at high bleeding risk, particularly those without high ischaemic risk.”
“Recent evidence suggests that withdrawal of aspirin after 1 to 3 months of DAPT, followed by P2Y12 inhibitor monotherapy may reduce bleeding while preventing recurrent ischaemic events compared with 12 months of DAPT.”
“No previous randomized trials have assessed early aspirin discontinuation in acute MI patients who achieve early, complete revascularization with modern stents.”
“This all-comer real-world trial recruited only 30% of the planned participants and was unable to address the primary question definitively. However, there was no evidence that DAPT given for 12 months conferred any additional benefit.”
Until adequately powered trials pin down exactly who can safely drop aspirin, abandoning the guideline-recommended 12 months risks recurrent thrombosis in patients who still need protection.
“Until adequately powered randomised controlled trials demonstrate a clinically meaningful identification of those patients, we should continue to adhere to the current guideline-recommended 12-month minimum DAPT duration following ACS.”
“We failed to demonstrate the noninferiority of aspirin-free monotherapy initiated immediately after PCI with regard to the ischemic primary endpoint over 12 months.”
“Overall, these findings suggest that in acute coronary syndrome patients undergoing PCI, very early aspirin withdrawal does not reduce early bleeding and significantly increases ischemic events at 30 days.”
In asymptomatic severe aortic stenosis, should we offer TAVR now or continue surveillance, given trial endpoints and durability data remain contested?
Fix it early
Waiting for symptoms risks irreversible heart damage and sudden death, and trials show early valve replacement cuts later hospitalizations and unplanned procedures with no clear downside.
“Aligning TAVR coverage with approved FDA indications, including asymptomatic AS”
“With no demonstrated clinical penalty for TAVR, these trial results strongly support a change to the practice and current guidelines for the treatment of aortic stenosis patients.”
“In my opinion, applying the same criteria used with symptomatic patients is beneficial for patients, meaning that, in patients with low-to moderate surgical risk, if we accept the results of TAVI trials, the transcatheter option is entirely acceptable.”
José Antonio Baz Alonso, MD · Interventional cardiologist · REC Interv Cardiol ↗
“These trial data are the first suggesting consideration of TAVI in asymptomatic severe AS is indicated before the onset of clinical decline associated with progression of valvular dysfunction.”
The trials leaned on soft endpoints, skipped a surgery comparison arm, and we still don't know how these valves hold up over decades — so committing a symptom-free patient to a valve is premature.
“The EARLY TAVR trial does not establish a meaningful patient-centered benefit for asymptomatic Medicare beneficiaries”
NCHR · National Center for Health Research · NCHR ↗
“There was hope among some members of the community that we would come up with a level I recommendation for asymptomatic aortic stenosis, and we just didn’t feel that the evidence was clear enough.”
“The endpoint choice and the omission of a SAVR arm means the trial doesn’t fully inform the decision regarding the timing of aortic valve intervention in patients with asymptomatic but severe AS.”
·
Undecided
“An asymptomatic person is really hard to make much better. If the patient is not complaining of anything, I think the evidentiary bar has to be quite high.”
John M. Mandrola · Electrophysiologist · Medscape ↗
“I don't think we can say this is a level 1 recommendation. I think level 1 is a bridge too far.”
David J. Cohen · Director of clinical and outcomes research · Medscape ↗
“The endpoint choice and the omission of a SAVR arm means the trial doesn’t fully inform the decision regarding the timing of aortic valve intervention in patients with asymptomatic but severe AS.”
John M. Mandrola · Electrophysiologist; Medscape commentator · Medscape ↗
Named experts we found publicly on record — a sample, not a representative poll of the field.
9Fix it early39unplaced3Watch and wait
Named experts on the record — a snapshot from the scan, not a poll. The measured clinician split builds below.
Where do you land?
No votes yet — the measured split appears at 10.
Some details are pending source verification and are withheld until confirmed.
Who: Adults ≥65 with moderate AS plus at least one at-risk feature·61 sources
On the board:since Jun 23, 2026 (4 mo)— time live on Synapse
In statin-treated patients with diabetes or atherosclerosis but no prior MI/stroke and LDL >=90, should a 25% relative reduction in first events justify routinely adding evolocumab?
Expand to high-risk primary prevention
A large trial now shows evolocumab cuts first heart attacks and strokes in these patients, so waiting for an event before lowering LDL hard means letting preventable damage happen.
“treatment with the PCSK9 inhibitor evolocumab led to a lower risk of first major adverse cardiovascular events”
“The results from the VESALIUS-CV trial represent the first demonstration of improved cardiovascular outcomes with a PCSK9 inhibitor, or any nonstatin for that matter, in patients without a previous heart attack or stroke who are already being treated with a high-intensity lipid-l”
“I think the clinical implication is clear: we should be more aggressive with high-risk primary prevention patients with diabetes. That means not just targeting below 70 mg/dL with a statin, but adding a PCSK9 inhibitor to get them closer to 40 mg/dL.”
Nicholas A. Marston · Preventive cardiologist · TCTMD ↗
“VESALIUS-CV is an important and practice-changing trial. It demonstrates that more intensive lipid lowering therapy earlier in the atherosclerotic disease process is better to reduce major cardiovascular events.”
Nicholas Marston · VESALIUS-CV investigator; Brigham and Women's Hospital · EurekAlert/ACC ↗
“The first myocardial infarction should not be considered the beginning of the treatment; it should be considered the failure of our prevention strategy.”
Gaetano M. De Ferrari · VESALIUS-CV investigator · HCPLive ↗
“The VESALIUS-CV results support intensive LDL-cholesterol lowering—one could argue maybe to a range of around 40mg/dL—even in patients without a prior event”
Pamela B. Morris · Preventive cardiologist · MedPage Today ↗
Don't broaden yet
The absolute benefit in patients who've never had an event is smaller than in secondary prevention, and treating this huge group with a costly drug for years may not be worth it without cost-effectiveness and long-term data.
“As much as we do like [PCSK9 inhibitors] and use them, we have to always think about cost”
Karen Aspry · Cardiologist and lipid specialist · TCTMD ↗
“show the benefit of evolocumab in a high-risk primary prevention patient population... but raise additional questions about long-term results, cost-effectiveness and age of treatment in younger, lower risk patients”
“show the benefit of evolocumab in a high-risk primary prevention patient population... but raise additional questions about long-term results, cost-effectiveness and age of treatment in younger, lower risk patients”
Undecided
Roger Blumenthal · Guideline chair · TCTMD ↗Erin A. Bohula · PI VESALIUS-CV · MedPage Today ↗Erin A. Bohula · PI presenter · NEJM ↗
“We are seeing a similar effect in this primary prevention cohort.”
In patients who have tolerated one month of dual antiplatelet therapy after PCI for acute coronary syndrome, should ticagrelor monotherapy be the default next step, or should 12 months of dual therapy remain the default outside of high bleeding risk?
Drop aspirin at one month
Pooled patient-level data from the ticagrelor-monotherapy trials show clearly less bleeding with no signal of more heart attacks or stent thrombosis, and bleeding after a stent carries its own mortality — so the year of aspirin is a habit, not a requirement, in patients who look stable at 30 days.
“The guidelines are based on an insufficient evidence base.”
Gregg Stone · Interventional cardiologist · TCTMD ↗
Twelve months stays the default
The monotherapy trials were mostly noninferiority designs, heavily enrolled in East Asia, and thin on STEMI and complex anatomy — so calling one month enough for everyone stretches the data past what it can carry, and a missed stent thrombosis is not a nuisance bleed.
“This endorsement is likely to raise debate because P2Y12 inhibitor monotherapy trials have been criticized for design heterogeneity, a predominant focus on bleeding, and noninferiority frameworks for ischemic outcomes.”
“We failed to demonstrate the noninferiority of aspirin-free monotherapy initiated immediately after PCI with regard to the ischemic primary endpoint over 12 months.”
Pedro Lemos · NEO-MINDSET PI · ACC ↗Sanjay Kaul · Cedars-Sinai · JACC ↗
“Dual antiplatelet therapy with aspirin and an oral P2Y12 inhibitor is indicated for at least 12 months as the default strategy in patients with ACS who are not at high bleeding risk.”
Undecided
“the 2025 ACC/AHA ACS guidelines remain an area that's still controversial”
“The body of data over the past five-to-eight years is compelling and strongly supports consideration of complete revascularization in patients with ACS”
Patients affected:Millions of patients· routine decision after every heart attack stent
›The evidence
What we know
✓Aspirin plus a potent P2Y12 blocker for a year prevents clots but reliably causes more bleeding.
✓In the ticagrelor-monotherapy trials, stopping aspirin early cut bleeding without an obvious rise in ischemic events.
✓US and European guidelines now disagree: the 2025 ACC/AHA guideline calls early ticagrelor monotherapy a strong recommendation, while ESC is more cautious and waits three to six months.
✓Bleeding after stenting is not benign — it tracks with worse survival, which is why shortening therapy is attractive at all.
What's still unknown
?Whether the results hold in patients underrepresented in the trials: STEMI, left main, bifurcations, long multivessel stenting.
Quotes and engagement counts are scan-reported and link to their primary source — not yet independently verified.
Specific patients
Outlook: Likely settled by new data around Apr 2028
In symptomatic patients with severe tricuspid regurgitation and a high risk of heart failure events, should transcatheter tricuspid intervention now be offered as prognosis-changing therapy on the strength of a single small open-label trial, or restricted to symptom relief until larger, more diverse trials replicate it?
Treat for hard outcomes now
A randomized trial now shows fewer deaths and heart failure admissions out to three years, the procedure is safe in trained hands, and elderly patients with severe leak deteriorate while we wait for a perfect trial.
“I think most people would agree, as clinicians, heart failure hospitalization is one of the worst things that can happen to a patient.”
“If you hold patients for another year, they’re not necessarily dying, but they do need to be treated.”
Gilbert Tang · Mount Sinai structural surgeon · TCTMD ↗
“What both of these studies provide is an extension of what we saw from the pivotal trials. We continue to see safety, [and] we continue to see efficacy in the real world.”
“This resulted in a relative reduction of 60% of the combined primary endpoint of mortality and heart failure hospitalization, with a highly statistically significant P value of 0.0001.”
Jörg Hausleiter · LMU Munich; TRIC-I-HF PI · TCTMD ↗
“This resulted in a relative reduction of 60% of the combined primary endpoint of mortality and heart failure hospitalization, with a highly statistically significant P value of 0.0001.”
“We have shown that [T-TEER] combined with standard-of-care medical therapy significantly reduces the long-term need for hospitalization for recurrent [HF] at two years, compared with standard-of-care medical therapy alone.”
The survival signal comes from a small, open-label trial at a handful of expert German centers where patients knew they were treated and drug therapy may not have been pushed hard — every prior program in this space delivered better symptoms and nothing more.
“To me, that’s going to be the Achilles’ heel of valve replacement [and] figuring that out.”
“For patients with severe tricuspid regurgitation, transcatheter tricuspid-valve replacement was superior to medical therapy alone for the primary composite outcome, driven primarily by improvements in symptoms and quality of life.”
In revascularized post-MI patients with preserved EF on modern guideline therapy, should clinicians routinely stop the beta-blocker or continue it indefinitely?
Stop the beta-blocker
Modern trials in patients with preserved EF show no survival or event benefit, so continuing only adds side effects, fatigue, and pill burden with nothing to gain.
“Beta-blockers have long been a foundational treatment after acute MI; however, supporting evidence is derived from trials that predate modern standards of care − before the time of routine reperfusion, invasive management, potent antiplatelet therapies and statins. Re-examining t”
“Based on the REDUCE-AMI trial results, I would recommend that routine beta-blockers for patients like those included in that trial (revascularized 1- or 2-vessel disease and LVEF ≥50%) is no longer necessary.”
“Differences between the groups with respect to hospitalisation for cardiovascular reasons and the negative effect on blood pressure levels, together with the absence of quality-of-life improvement do not support interruption of a chronic beta-blocker treatment in post-MI patients”
Beta-blockers still guard against arrhythmias and adverse remodeling, and the newer trials may miss harder, longer-term events the older data captured.
“Patients post-MI with mildly reduced LVEF (40−49%) but without HF represent a sizeable population.”
“REBOOT-CNIC, BETAMI, and DANBLOCK examine whether long-term beta-blockers are still needed in myocardial infarction, especially if heart function remains preserved.”
“At 30 days, a primary outcome event... was 61% lower in the catheter-directed therapy plus anticoagulation group compared with the anticoagulation-only group.”
“In contrast to interventions for myocardial infarction or stroke, there have been very few advances in the treatment of pulmonary embolism over the last 20 years. This has led to a considerable unmet clinical need that we can’t ignore.”
Viktor Kočka · PRAGUE-26 lead; Charles University Prague · Medical Dialogues ↗
“There was no significant difference in death, recurrent PE, or even 6-minute walk at 30 days, which indicates functional status.”
“If we're going to extend the therapy downstream to slightly healthier patients, this trial is not necessarily telling us to do that.”
Jay Giri · Interventional cardiologist; PE trialist · MedPage Today ↗
“The HI-PEITHO trial was the first RCT whose findings demonstrated that catheter-directed fibrinolysis reduces early clinical deterioration in select patients with intermediate-risk PE.”
“If the right patients are selected for this procedure, it can prevent patients from deteriorating and it can do so at an acceptably low risk of bleeding complications.”
“Moreover, she stressed that it’s necessary to wait on the forthcoming PEITHO-3 trial results “before we can definitely advertise catheter-directed thrombolysis as the primary treatment of intermediate-high-risk PE.””
Irene M. Lang · ESC discussant; Medical University of Vienna · TCTMD ↗
“The key takeaway message is that we are going to have new pulmonary embolism guidelines in Europe in 2027, and I hope that these data together with the previously published data will change those guidelines.”
Insufficient evidence (1 studies, 9371 patients) to determine the effect of catheter-based mechanical thrombectomy plus anticoagulation on the outcome in Acute pulmonary embolism.
Supporting
+Comparative Efficacy and Safety of Mechanical Thrombectomy and Anticoagulation in Intermediate- to High-Risk Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis
“We realized that people think they agree, but when one says it, it’s not the same as when another doctor says it.”
Lars Køber · ESC HF guideline leadership · TCTMD ↗
“Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF.”
“Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF.”
“We've got a culture of deferring to the next visit and never getting around to starting GDMT, even though it's truly lifesaving, and the consequences of not starting therapy are fatal and nonfatal events for our patients.”
“When all methodological and analytical issues are accounted for, the data from the FINEARTS trial provide little evidence for a favorable effect of finerenone on health status in patients with HFpEF or HFmrEF.”
“Given that finerenone was beneficial in patients already receiving an SGLT2 inhibitor, our findings point to finerenone as a new second pillar in HFmrEF/HFpEF.”
Scott Solomon · FINEARTS-HF leadership (quoted in coverage of second-pillar framing) · HCPLive/LinkedIn recap ↗
“So, this is a really welcome addition to the breadth of evidence that supports the use of MRAs.”
“the lack of a compelling statistical interaction in these subgroups and the lack of consistency of this trend in other key secondary endpoints examined”
Akshay S. Desai · FINEARTS investigator; Brigham and Women's · Healio ↗
“Until additional data emerges, I believe that in the absence of any mortality benefit overall, and the apparent absence or minimal benefit in this subgroup of patients, there is not a compelling need to initiate finerenone in patients who have no recent worsening heart failure event.”
“The guideline advances a new approach to risk assessment through a novel risk score, sets lower LDL-C goals, and recommends measuring Lp(a) at least once.”
“While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren't within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would”
“The guideline addresses the evaluation, management, and monitoring of individuals with lipid disorders, including high blood cholesterol, hypertriglyceridemia, and elevated Lp(a).”
“The Guideline-at-a-Glance provides a visual overview of key concepts from the 2026 ACC/AHA Multisociety Dyslipidemia Guideline, highlighting major updates in risk assessment and treatment goals.”
“Given the enhanced accuracy of the PREVENT-ASCVD equations, which provide risk estimates that are approximately 40% to 50% lower than the PCE, the current guideline panel selected the 10-year estimated ASCVD risk threshold of ≥3% for beginning consideration of [lipid-lowering the”
“This is why we are emphasizing checking cholesterol at a young age — not because we want to start everybody on statins early, but because having high cholesterol for a long time makes it more likely that someone will have a heart attack or stroke.”
“It's still too early to be advocating treating every vulnerable plaque that you see, but it’s an interesting piece of data because we all commonly see high-risk features that we know predict future events, but we don’t know what we should do about them.”
“Lack of a decades-long randomized controlled trial is not the same as a lack of evidence.”
Ann Marie Navar · Preventive cardiologist · Healio ↗
“There is indeed overwhelming evidence supporting our practice-changing Guideline.”
Roger Blumenthal · Preventive cardiologist · Medscape ↗
“Key updates to this guideline include: The use of the American Heart Association PREVENT-ASCVD equations to guide primary-prevention and lipid-lowering therapy decisions.”
AHA Science · American Heart Association Science account summarizing guideline authors · X @AHAScience ↗
“The main message is that not everyone needs a CAC scan and CAC zero should not be used as a veto against statin therapy.”
Michael Shapiro · Preventive cardiologist · STAT ↗
“We say try to achieve a 120 to 129 target in the first instance and you can opt out if the patient isn't tolerating that treatment or can't achieve that target.”
John William McEvoy · ESC hypertension guideline chair · TCTMD ↗
“There’s definitely less disparity now.”
Paul Whelton · U.S. hypertension guideline leader · TCTMD ↗
James Stein · Preventive cardiologist · Medscape ↗
“Everybody's getting excited about them, but we must wait on the results. You don't know for sure until you see the data.”
Karol Watson · Preventive cardiologist · UCLA Health ↗
“Nearly a quarter of the world's population has elevated levels of [lipoprotein(a)], putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes.”
“This change is driven by new trial evidence confirming that more intensive BP treatment targets reduce CVD outcomes across a broad spectrum of eligible patients.”
“By addressing individual risks earlier and offering more tailored strategies across the lifespan, the 2025 guideline aims to aid clinicians in helping more people manage their blood pressure.”
Daniel Jones · 2025 BP guideline writing committee chair · MedPage Today ↗
“Of the 53 class one recommendations, only 10 or 22% were backed by randomized controlled trials.”
“Taken together, these studies show that the absence of CAC does not neutralize the long-term risk associated with sustained exposure to elevated LDL-C.”
James H. Stein · Preventive cardiologist · Substack ↗
“If it's high, we would treat your LDL very aggressively.”
Leslie Cho · Cleveland Clinic; guideline co-author · New York Times ↗
Ann Marie Navar · 2026 dyslipidemia writing committee member · HCPLive ↗
Roger Blumenthal · 2026 dyslipidemia guideline chair · TCTMD ↗
“Given the enhanced accuracy of the PREVENT-ASCVD equations, which provide risk estimates that are approximately 40% to 50% lower than the PCE, the current guideline panel selected the 10-year estimated ASCVD risk threshold of ≥3% for beginning consideration of [lipid-lowering”
“But I do not support this recommendation and did not support it even before the recent Lp(a)HORIZON topline results were reported as negative for the clinical benefit of lowering Lp(a) with pelacarsen.”
James H. Stein · Preventive cardiologist · Substack ↗
“In general, lower LDL is better, especially for people at increased risk for a heart attack or stroke.”
“I’ve been a believer in measuring Lp(a) for a long time, way before it was in vogue. I used to test it in patients who came in with premature MI.”
Deepak L. Bhatt · Mount Sinai Fuster Heart Hospital · HCPLive ↗
“While I think our results would not support adding Lp(a) to the PREVENT equations, they confirm that on an individual-patient basis Lp(a) can add information.”
Harpreet Bhatia · University of California San Diego · Medscape ↗
“That's a sea change. A person's lifetime risk is what counts.”
Steven Nissen · Cleveland Clinic preventive cardiology · NPR ↗
“These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management.”
“The most important highlight is that [the statement] tried to address any concerns that fewer people would be treated because of using the PREVENT equations.”
Deepak L. Bhatt · Quoted as Healio perspective on HORIZON · Healio ↗
“These are not the results we hoped for, but they provide important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes and may help inform future approaches to cardiovascular risk management.”
Shreeram Aradhye · Chief Medical Officer · Novartis ↗
“We know 80% or more of cardiovascular disease is preventable and elevated LDL cholesterol, sometimes referred to as 'bad' cholesterol, is a major part of that risk.”
James H. Stein · Preventive cardiologist · Substack ↗
“So, we need to test universally, at least once in everyone, identify those with high alkyl A, and then use that for cascade screening out to siblings, to children, and to children of siblings, all of whom may have elevated Lp(a).”
“In recent years, however, the NLA, the European Society of Cardiology, the European Atherosclerosis Society, and other societies have begun recommending that adults have Lp(a) checked at least once in their lifetime, and the American College of Cardiology and American Heart Association have since made a similar recommendation for all adults.”
Dinesh Kalra · Preventive cardiologist (Pharmacy Times commentary) · Pharmacy Times ↗
“There are trial differences and drug differences, so there is still hope that Lp(a)-targeted therapy might pan out.”
“Because the PREVENT equations use more contemporary data, the risk estimate that we get is lower than the Pooled Cohort Equations.”
Sadiya Khan · Northwestern; PREVENT developer · STAT ↗
“Certainly, in secondary prevention for people with atherosclerosis, they benefit when we drop LDL-C down to under 40 mg/dL; even under 30 or 20 mg/dL, it looks like the benefit continues.”
“I think that the Class 1 recommendation of less than 55 mg/dL for basically everyone with established ASCVD is further ahead than the US guidelines and is a stronger level of recommendation.”
Michelle O'Donoghue · Brigham and Women's Hospital · Medscape ↗
“I think the result was indeed somewhat unexpected for us, because this is exactly the patient population where we are now doing left atrial appendage closure.”
“We really have to have a good conversation with them. We’ve all seen patients who have a CHA2DS2-VASc score of 0 and then a few months down the road they have a stroke.”
“The Watchman FLX left atrial appendage closure device may be considered as an alternative to NOACs in a shared decision-making process with atrial fibrillation patients who are deemed suitable for long-term oral anticoagulants.”
“In this multicenter randomized trial, a strategy of catheter-based left atrial appendage closure did not achieve non-inferiority compared to physician-directed best medical care in older patients with atrial fibrillation at high risk of stroke and bleeding.”
“It's both one of the most biased and most consequential studies I have reviewed in years.”
John Mandrola · Electrophysiologist; Sensible Medicine · Sensible Medicine ↗
“We expected that catheter-based LAA closure would be comparable to physician-directed standard medical care often using blood-thinning anticoagulant medications. However, this was not the case in this trial of older patients at very high risk of bleeding and stroke.”
“Watchman FLX left atrial appendage closure should be considered as an alternative to NOACs in a shared decision-making process with Afib patients who are deemed suitable for long-term oral anticoagulation.”
Saibal Kar · CHAMPION-AF presenter; Los Robles Medical Center · MedPage Today ↗
“I think with left atrial appendage occlusion, the complication rates, especially outside of expert centers, aren't trivial.”
“The burden of proof lies with LAAO, not with the control arm. The issue is the strength of the evidence supporting LAAO, not medical therapy, which remains the reference standard.”
Davide Capodanno · University of Catania; EuroIntervention EiC · X ↗
“The fact that LAAC can be completed safely at the time of AFib ablation makes it a possible alternative to long-term oral anticoagulation.”
“In an ablation population with a CHA2DS2-VASc score of at least 2 in men and at least 3 in women, it is reasonable to consider left atrial appendage closure instead of continued oral anticoagulation.”
“If electrophysiologists were as skilled in critical appraisal of evidence as they are with procedures, the results of the OPTION trial comparing two strategies of stroke prevention after atrial fibrillation (AF) ablation would not lead to more percutaneous left atrial appendage”
John M. Mandrola · Electrophysiologist; Medscape · Medscape ↗
“An important note is that the HAS-BLED score was only 1.3, which means we basically picked patients who could take long-term anticoagulation.”
Saibal Kar · Interventional cardiologist; CHAMPION-AF presenter · Healio ↗
“The CLOSURE-AF trial did not show noninferiority for LAA closure compared with anticoagulation.”
“We expected that catheter-based LAA closure would be comparable to physician-directed standard medical care often using blood thinning anticoagulant medications.”
“While I am biased by being an author on this paper, I see the data as strengthening the case against using LAAC as a substitute for oral anticoagulation.”
“CHAMPION-AF, which was presented as a late breaker at the 2026 American College of Cardiology meeting, will surely be promoted as a “positive” trial, but the actual data are far too weak to overturn one of medicine’s best-supported treatments.”
John M. Mandrola · Electrophysiologist; Medscape · Medscape ↗
“the actual data are far too weak to overturn one of medicine’s best-supported treatments.”
“The CLOSURE-AF study raises the burden of proof to demonstrate at worst equivalence, if not superiority, of the device, and I don’t think that CHAMPION-AF convincingly provided that proof.”
Gregory M. Marcus · UCSF; NEJM editorialist · TCTMD ↗
“In patients with nonvalvular atrial fibrillation suitable for anticoagulation, left atrial appendage closure using the Watchman FLX device, at 3 years was noninferior to NOACs for the composite primary endpoint.”
Andrew Goldsweig · Interventional cardiologist · TCTMD ↗
“Randomized trials of left atrial appendage closure previously garnered an American College of Cardiology–American Heart Association class IIA recommendation that was restricted to patients with atrial fibrillation at high risk for stroke who had contraindications to long-term anticoagulation.”
Gregory M. Marcus · UCSF; NEJM editorialist · NEJM ↗
“I see the data as strengthening the case against using LAAC as a substitute for oral anticoagulation.”
John Mandrola · Electrophysiologist; Sensible Medicine · Sensible Medicine ↗
“I'm not sure which will be worse, EARLY TAVR or OPTION. Med science is for asking important questions--not designing trials to be positive”
John Mandrola · Electrophysiologist; Medscape · X ↗
“These data suggest that the use of left atrial appendage closure as a possible alternative to oral anticoagulation should be part of a shared decision-making process with patients who have atrial fibrillation.”
“Left atrial appendage closure was associated with a higher risk of the combined primary endpoint of stroke, systemic embolism, major bleeding and cardiovascular or unexplained deaths over a median follow-up time of 3 years in these elderly, high-risk patients.”
“If electrophysiologists were as skilled in critical appraisal of evidence as they are with procedures, the results of the OPTION trial comparing two strategies of stroke prevention after atrial fibrillation (AF) ablation would not lead to more percutaneous left atrial appendage closure (LAAC) procedures.”
John Mandrola · Electrophysiologist; Medscape · Medscape ↗
“I believe that electrophysiology is on the brink of a large wave of overtreatment.”
“The current guidelines rightly -- American and European -- remain cautious with the class 2b recommendations, reflecting a field where clinical enthusiasm has clearly outpaced high quality evidence.”
“Patients with ACS are at the highest risk for cardiovascular complications both acutely and chronically, which emphasises the importance of staying up-to-date on the most recent evidence presented in this guideline.”
“For example, the guideline includes Class 1 recommendations both for DAPT for 1 year (to reduce ischemic events) and for switching to ticagrelor monotherapy after 1 month of tolerating DAPT (to reduce bleeding).”
“Antiplatelet and anticoagulation trials like NEO-MINDSET, TARGET FIRST, DUAL-ACS test earlier withdrawal of aspirin or oral anticoagulants to reduce bleeding risk.”
“In the absence of demonstrable benefit, and certain signals of harm that are consistent with prior data, really we should be giving patients three months of antiplatelet therapy after a heart attack and not 12 months.”
“Beta blocker therapy is one of the areas where there continues to be additional clinical trials that have been released since the finalization of the 2025 document.”
“Immediate P2Y12 inhibitor monotherapy with withdrawal of aspirin is not as protective as DAPT for ischemic events in patients with ACS after PCI, even though it does reduce bleeding.”
Pedro A. Lemos · NEO-MINDSET investigator · Healio ↗
“In low-risk patients, and not only in high-bleeding-risk patients, an aspirin-free strategy is possible after 1-month DAPT.”
“Among patients who had undergone successful PCI for acute coronary syndromes, potent P2Y12 inhibitor monotherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of death or ischemic events at 12 months.”
Pedro A. Lemos · NEO-MINDSET investigator · NEJM ↗
“Among patients who had undergone successful PCI for acute coronary syndromes, potent P2Y12 inhibitor monotherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of death or ischemic events at 12 months.”
“We failed to demonstrate the noninferiority of aspirin-free monotherapy initiated immediately after PCI with regard to the ischemic primary endpoint over 12 months.”
Pedro A. Lemos · NEO-MINDSET investigator · ESC coverage ↗
“My dear colleagues, the current recommendations on the duration of DAPT are obsolete.”
“Immediate P2Y12 inhibitor monotherapy with withdrawal of aspirin is not as protective as DAPT for ischemic events in patients with ACS after PCI, even though it does reduce bleeding.”
Insufficient evidence (1 studies, 15391 patients) to determine the effect of 3-month dual antiplatelet therapy (dapt) followed by monotherapy on the outcome in Coronary Artery Disease.
Supporting
+Different antiplatelet therapy in high bleeding risk patients after PCI: a network meta-analysis
“Given the benefits observed and the lack of harm, early TAVR may be preferred to CS in patients with asymptomatic severe AS, especially when combined with the challenges of timely symptom recognition and prompt treatment in real-world settings.”
“Its results strongly favored TAVR, but two glaring design flaws remove nearly all its clinical value.”
John Mandrola · Electrophysiologist / commentator · Medscape ↗
“We shouldn’t rely on the development of what are cited as class II recommendations to make a treatment decision.”
Patrick O'Gara · Brigham and Women's Hospital · TCTMD ↗
“These findings provide a strong rationale for prompt intervention in patients with asymptomatic severe aortic stenosis at least to prevent progression to acute valve syndrome and poor outcome.”
“They called it a conversion when those clinical surveillance patients went on to undergo TAVR due to symptoms, but that should have been viewed as a crossover.”
“Registry study showed 50% increase in mortality at 3y with delayed TAVR, but mortality was not increased in EARLY-TAVR at median f/u of 3.8y (HR 0.93, 0.60-1.44). Should we chase potentially confounded data to justify early TAVR?”
“There's a lot to worry about in the exuberance to intervene on people-with-no-complaints, not least because even the diagnosis of severe AS is not always correct.”
John Mandrola · Electrophysiologist; Medscape · Medscape ↗
John M. Mandrola · Electrophysiologist / trial critic · Medscape ↗
“Among patients with asymptomatic severe aortic stenosis, a strategy of early TAVR was superior to guideline-recommended clinical surveillance in reducing the composite end point of death, stroke, or unplanned hospitalization for cardiovascular causes.”
Philippe Généreux · EARLY TAVR investigator · NEJM ↗
“I personally think this will be a fairly nuanced conversation with the patient.”
“The totality of the evidence does not support endorsing early AVR, especially TAVR, as the preferred therapy for low-risk patients with asymptomatic severe AS.”
“Expanding early or preemptive interventional treatment to all asymptomatic patients who might formally meet hemodynamic and anatomical criteria may be premature. For now, awaiting symptoms remains a justifiable strategy.”
Stefan Blankenberg · University Heart & Vascular Center Hamburg · TCTMD ↗
“Even at 6 months, one in four patients has symptoms and conversion to treatment.”
Anna Sonia Petronio · Pisa University Hospital; structural cardiologist · TCTMD ↗
“The EARLY TAVR trial does support early intervention as the preferred strategy, independent of guideline indications.”
Philippe Généreux · EARLY TAVR PI; Morristown Medical Center · ACC ↗
“I think the message is, as soon as a patient has severe aortic stenosis, they should be referred. And we should treat the patient as soon as possible.”
“Expanding early or preemptive interventional treatment to all asymptomatic patients who might formally meet hemodynamic and anatomical criteria may be premature.”
“There’s a lot to worry about in the exuberance to intervene on people-with-no-complaints, not least because even the diagnosis of severe AS is not always correct.”
John M. Mandrola · Electrophysiologist; Medscape · Medscape ↗
“All asymptomatic patients need to have TAVR or SAVR? That is a wrong message. For us to figure out that gray zone, I think we need more evidence and some of these subgroup analyses will help us.”
“The original EARLY TAVR data galvanized the entire valve community to take a more active approach to the management of severe aortic stenosis, to think ahead, to prepare patients for intervention, and then offer them intervention if it is anatomically safe and suitable.”
Bernard Prendergast · Cleveland Clinic London; EARLY TAVR discussant · TCTMD ↗
“We shouldn’t rely on the development of what are cited as class II recommendations to make a treatment decision.”
Patrick O’Gara · Brigham and Women’s Hospital · TCTMD ↗
“There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend 'watchful waiting' until symptoms develop.”
“There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend ‘watchful waiting’ until symptoms develop.”
“These results shatter 60 years of ingrained belief on the treatment for severe aortic stenosis, with guidelines that currently recommend ‘watchful waiting’ for intervention until symptoms develop.”
“An asymptomatic person is really hard to make much better. If the patient is not complaining of anything, I think the evidentiary bar has to be quite high.”
John Mandrola · Electrophysiologist; Medscape commentator · Medscape ↗
“What we saw is 26% of the patients convert to symptoms within 6 months, 50% convert within a year, and more than 70% needed aortic valve replacement by 2 years.”
4 studies (31,872 patients, 2 RCTs) provide high-certainty evidence for benefit of evolocumab for the outcome in stable atherosclerotic cardiovascular disease.
Supporting
+Evolocumab treatment reduces carotid intima-media thickness in paediatric patients with heterozygous familial hypercholesterolaemia
+Efficacy and safety of evolocumab in statin-treated patients with cardiovascular risk factors: a systematic review and meta-analysis
+Early evolocumab improves lipid profile, inflammation and short-term outcomes in non-revascularized CHIP-NSTEACS patients: a retrospective cohort study
“In the absence of demonstrable benefit, and certain signals of harm that are consistent with prior data, really we should be giving patients three months of antiplatelet therapy after a heart attack and not 12 months.”
Shamir Mehta · COMPLETE / COMPLETE-2 lead · PHRI ↗
“These findings highlight that when complete revascularization meets personalized pharmacotherapy, abbreviated DAPT emerges as a safe and effective strategy for carefully selected patients.”
“Among patients with STEMI and multivessel disease, immediate complete revascularisation was not shown to be non-inferior to staged complete revascularisation during the index admission.”
“These [data] are by far the strongest evidence that complete revascularization improves important clinical outcomes in patients with acute MI and multivessel coronary disease.”
“Beta blocker therapy is one of the areas where there continues to be additional clinical trials that have been released since the finalization of the 2025 document.”
“Given our findings in patients with signs of heart failure, it seems prudent to limit immediate complete revascularisation to stable STEMI patients with multivessel disease at low clinical risk.”
“In the OPTION-STEMI trial, immediate complete revascularisation was not noninferior to staged complete revascularisation during index hospitalisation.”
“In the absence of demonstrable benefits and real concern of harm, I believe that less is more, and patients should be treated with DAPT for only 3 months after an MI.”
Insufficient evidence (1 studies, 15391 patients) to determine the effect of 3-month dual antiplatelet therapy (dapt) followed by monotherapy on the outcome in Coronary Artery Disease.
Supporting
+Different antiplatelet therapy in high bleeding risk patients after PCI: a network meta-analysis
“I have the TRILUMINATE trial, which was one of the most biased trials in all of cardiology, because one group got the procedure, the other group got tablets, and the primary endpoint was driven only by quality of life changes.”
2 studies (1,292 patients) provide low-certainty evidence against benefit of transcatheter tricuspid valve intervention (ttvi) for the outcome in Severe tricuspid valve regurgitation.
Dissenting
−Impact of right ventricular-pulmonary artery coupling on outcomes in tricuspid regurgitation – insights from the international TRIGSTRY
−Transcatheter tricuspid valve intervention versus medical therapy in severe tricuspid regurgitation: a systematic review and bayesian meta-analysis of randomized controlled trials
Insufficient evidence (1 studies, 1292 patients) to determine the effect of transcatheter tricuspid valve intervention (ttvi) on Heart Failure Hospitalization in Severe tricuspid valve regurgitation.
Supporting
+Transcatheter tricuspid valve intervention versus medical therapy in severe tricuspid regurgitation: a systematic review and bayesian meta-analysis of randomized controlled trials
Insufficient evidence (1 studies, 1292 patients) to determine the effect of transcatheter tricuspid valve intervention (ttvi) on Cardiovascular Mortality in Severe tricuspid valve regurgitation.
Dissenting
−Transcatheter tricuspid valve intervention versus medical therapy in severe tricuspid regurgitation: a systematic review and bayesian meta-analysis of randomized controlled trials
“examine whether long-term beta-blockers are still needed in myocardial infarction, especially if heart function (ejection fraction) remains preserved”
“REBOOT-CNIC and BETAMI-DANBLOCK examine whether long-term beta-blockers are still needed in myocardial infarction, especially if ejection fraction remains preserved.”
“In appropriately selected patients who survived a heart attack and do not have HF or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary.”
“For this population with AMI and revascularization and preserved LVEF and no other reason to use a beta-blocker (like hypertension or arrhythmias), I no longer prescribe beta-blockers.”
“My read on the totality of the data is that the benefit is mediocre at best when compared with [use in] heart failure with reduced ejection fraction.”
“The message should not be ‘stop beta-blockers after MI,’ but rather ‘consider withdrawal only when the residual ischemic and arrhythmic risk is truly minimal.’”
“The results across most trials were remarkably consistent, although a few — such as BETAMI and DANBLOCK — showed a small signal toward reduction in MI, making it even more important to synthesize all available data.”
“While the REDUCE-AMI trial did not demonstrate benefit, there are additional trials underway and guideline recommendations have not yet been revised.”
“Among patients discharged after invasive care for a myocardial infarction with a left ventricular ejection fraction above 40%, beta-blocker therapy appeared to have no effect on the incidence of death from any cause, reinfarction, or hospitalization for heart failure.”
Borja Ibanez · REBOOT principal investigator · NEJM ↗
“A meta-analysis of these patients found a 25% reduction in a composite endpoint of death, new MI, or heart failure. But I see four reasons to be cautious about this finding—mainly, that the reduction was small and statistically fragile.”
John Mandrola · Electrophysiologist; Medscape/Sensible Medicine · Medscape ↗
“In 2025, we have overturned a treatment paradigm that had gone unquestioned for decades. From now on, patients discharged after infarction with normal cardiac function will no longer receive beta-blockers.”
“Currently, more than 80 percent of patients with uncomplicated myocardial infarction are discharged on beta blockers. The REBOOT findings represent one of the most significant advances in heart attack treatment in decades.”
“Beta blocker therapy is one of the areas where there continues to be additional clinical trials that have been released since the finalization of the 2025 document.”
“In 2025, we have overturned a treatment paradigm that had gone unquestioned for decades. From now on, patients discharged after infarction with normal cardiac function will no longer receive beta-blockers.”
“don't rush out and everybody stop beta-blockers post myocardial infarction. These patients were very carefully selected.”
John G. F. Cleland · Heart-failure trialist · MedPage Today ↗
“In appropriately selected patients who survived a heart attack and do not have heart failure or left ventricular systolic dysfunction, routine continuation of beta-blockers indefinitely may not be necessary.”
“So my view is that for EF < 40%, there’s a crystal-clear indication, and for 40%-50%, beta-blockers seem to convey a benefit. We have good data on that I would say published as of today. And then > 50%, that’s a different ball game.”
“Beta blocker therapy is one of the areas where there continues to be additional clinical trials that have been released since the finalization of the 2025 document.”
“Discontinuation of a beta-blocker beyond the first year of myocardial infarction would be a reasonable strategy in selected stable post-MI patients without left ventricular systolic dysfunction or heart failure.”
John M. Mandrola · Electrophysiologist · Medscape ↗
“On balance, I think we should continue to offer beta-blockers following MI in patients with reduced LVEF, but it is reasonable to reevaluate whether to maintain beta-blockers after the dust has settled or about 4-6 weeks after the event.”
John Cleland · Heart failure trialist · Medscape ↗
“This trial will reshape all international clinical guidelines.”
Valentin Fuster · CNIC / Mount Sinai; REBOOT investigator · Mount Sinai ↗
“Among patients with a myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blocker therapy led to a lower risk of death or major adverse cardiovascular events than no beta-blocker therapy.”
Borja Ibáñez · REBOOT principal investigator · ScienceDaily ↗
“I would conclude that interruption of beta-blockers at 1 year vs continuation in post-MI patients did not lead to an increase in death, MI, or stroke.”
John M. Mandrola · Electrophysiologist / commentator · Medscape ↗
“From now on, patients discharged after infarction with normal cardiac function will no longer receive beta-blockers.”
Valentin Fuster · CNIC General Director; Mount Sinai Fuster Heart Hospital; REBOOT investigator · EurekAlert ↗
“Currently, more than 80 percent of patients with uncomplicated myocardial infarction are discharged on beta blockers. The REBOOT findings represent one of the most significant advances in heart attack treatment in decades.”
“We can now state with confidence that beta-blockers are beneficial in patients with mildly impaired heart function, and there remains reasonable uncertainty about their benefit in patients with normally functioning hearts.”
10 studies (165,196 patients, 2 RCTs) provide moderate-certainty evidence for benefit of beta-blockers for the outcome in ST segment elevation myocardial infarction.
Supporting
+Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction
+Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials
+Contemporary secondary prevention in survivors of ST-elevation myocardial infarction with and without chronic kidney disease: a retrospective analysis
+Usefulness of universal beta-blocker therapy in patients after ST-elevation myocardial infarction
Dissenting
−Impact of in-hospital oral beta-blockers initiation on long-term outcomes in ST-elevation myocardial infarction patients with cardiogenic shock
−Sustained beneficial effect of β-blockers on clinical outcomes after discontinuation in patients with ST elevation myocardial infarction
−Role of Soluble ST2 Levels and Beta-Blockers Dosage on Cardiovascular Events of Patients with Unselected ST-Segment Elevation Myocardial Infarction
